Srivastava discusses how his personal upbringing eventually intersected with a team that works to deliver over 90% of FDA-approved therapeutic drugs onto the global market.

Following a handful of clinical failures and changes to its leadership, FibroGen is trying to chart a more positive path forward by focusing on four strategic areas.

After Eli Lilly announced it would take measures to cap insulin prices, Novo Nordisk will reportedly follow suit. There may be strategic reasoning behind these moves.

Theravance Biopharma is discontinuing research activities for its JAK inhibitor program in lung inflammation and reducing its headcount by about 17%.

With recent years of acquisitions and divestitures in the rearview, Takeda can focus on what matters most: growing its brands.

For Med Ad News’ 36th annual special report, the publication’s editors rank the world’s top 50 companies that generate revenue from prescription medicines and healthcare products.